We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

62 hedge funds and large institutions have $23.6M invested in Galectin Therapeutics in 2018 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 9

89% more capital invested

Capital invested by funds: $12.5M → $23.6M (+$11.1M)

27% more funds holding

Funds holding: 49 → 62 (+13)

10% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 10

3.49% more ownership

Funds ownership: 10.49% → 13.99% (+3.5%)

7% more call options, than puts

Call options by funds: $1.12M | Put options by funds: $1.04M

Holders
62
Holders Change
+13
Holders Change %
+26.53%
% of All Funds
1.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
11
Reduced
10
Closed
9
Calls
$1.12M
Puts
$1.04M
Net Calls
+$78K
Net Calls Change
-$83K

Top Buyers

Rank Fund Capital Flow
1
EI
EAM Investors
California
+$1.49M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.17M
3
EGI
EAM Global Investors
California
+$1.06M
4
SM
Sabby Management
Florida
+$668K
5
BCM
BlueCrest Capital Management
Jersey
+$472K

Top Sellers

Rank Fund Capital Flow
1
US Bancorp
US Bancorp
Minnesota
-$397K
2
OAM
Oxford Asset Management
United Kingdom
-$161K
3
GWM
Geneos Wealth Management
Colorado
-$150K
4
CCM
Courage Capital Management
Tennessee
-$93.2K
5
NPF
Norris Perne & French
Michigan
-$93.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
26
LPL Financial
California
$112K +$110K +23,593 New
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$111K – – –
Charles Schwab
28
Charles Schwab
California
$102K – – –
LWAC
29
Laurel Wealth Advisors (California)
California
$101K +$99.7K +21,400 New
Barclays
30
Barclays
United Kingdom
$96K +$93.8K +20,123 New
JG
31
Jefferies Group
New York
$95K +$93.2K +20,000 New
MML Investors Services
32
MML Investors Services
Massachusetts
$83K -$44.8K -9,619 -35%
State Street
33
State Street
Massachusetts
$83K +$81.3K +17,450 New
RG
34
Rathbones Group
United Kingdom
$78K – – –
ECM
35
Element Capital Management
New York
$67K +$65.9K +14,144 New
JA
36
JOYN Advisors
Georgia
$61K +$59.6K +12,796 New
NPF
37
Norris Perne & French
Michigan
$50K -$93.2K -20,000 -66%
Wells Fargo
38
Wells Fargo
California
$50K -$1.4K -300 -3%
Verition Fund Management
39
Verition Fund Management
Connecticut
$48K +$47.5K +10,195 New
BSW
40
Buckingham Strategic Wealth
Missouri
$47K – – –
CF
41
Centaurus Financial
California
$47K – – –
DAS
42
Dynamic Advisor Solutions
Arizona
$47K – – –
Bank of America
43
Bank of America
North Carolina
$39K +$4.71K +1,010 +14%
UBS Group
44
UBS Group
Switzerland
$29K +$28.5K +6,122 New
IWM
45
IHT Wealth Management
Illinois
$28K – – –
Group One Trading
46
Group One Trading
Illinois
$24K +$24K +5,152 New
SEI Investments
47
SEI Investments
Pennsylvania
$18K – – –
IA
48
IFP Advisors
Florida
$17K – – –
Deutsche Bank
49
Deutsche Bank
Germany
$12K +$12.1K +2,598 +129,900%
LTFS
50
Ladenburg Thalmann Financial Services
Florida
$9K – – –
1
2
3

GALT Hedge Fund Activity: Q1 2018 in Review

62 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2018, worth a combined $23.6M — up 89% from $12.5M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new GALT positions and 9 closed out — a net gain of 13 holders — while 11 added to existing stakes and 10 trimmed.

The largest buyer was EAM Investors, opening a new position worth an estimated $1.49M. The largest seller was US Bancorp, exiting entirely with an estimated $397K sold.

  • 62 institutional investors held Galectin Therapeutics (GALT) as of Q1 2018, up from 49 in Q4 2017.
  • Funds reported $23.6M of Galectin Therapeutics stock for Q1 2018, up 89% quarter-over-quarter.
  • 22 funds opened new Galectin Therapeutics positions in Q1 2018 and 9 closed out, a net change of +13 holders.
  • The largest Galectin Therapeutics buyer in Q1 2018 was EAM Investors, an estimated $1.49M added.
  • The largest Galectin Therapeutics seller in Q1 2018 was US Bancorp, an estimated $397K sold.

Based on aggregated 13F filings for Q1 2018.